Flurbiprofen Sodium
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Others |
| Catalog number | BBF-03906 |
| CAS | 56767-76-1 |
| Molecular Weight | 266.24 |
| Molecular Formula | C15H12FNaO2 |
| Purity | ≥95% |
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-03906 | 5 g | $390 | In stock | |
| BBF-03906 | 25 g | $690 | In stock |
Online Inquiry
Add to cartCapabilities & Facilities
Fermentation Lab
4 R&D and scale-up labs
2 Preparative purification labs
Fermentation Plant
Semi pilot, pilot and industrial plant 4 Manufacturing sites 7 Production lines at pilot scale 100+ Reactors of 30-4000 L; 170+ reactors of 20 KL-30 KL; 24+ reactors of >100 KL 2 Hydrogenation reactors (200 L, 4Mpa and 1000L, 4Mpa)
Product Description
Flurbiprofen Sodium is a nonsteroidal anti-inflammatory drug (NSAID) derived from propionic acid. It functions as a potent inhibitor of cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins, which are mediators of pain, inflammation, and fever.
- Specification
- Properties
- Reference Reading
- Price Product List
| Related CAS | 5104-49-4 (free acid) |
| Synonyms | [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α-methyl-, sodium salt (1:1); 2-(2-Fluorobiphenyl-4-yl)propionic acid sodium salt; 2-Fluoro-α-methyl-4-diphenylacetic acid sodium salt; Flurbiprofen sodium salt; Ocufen; Ocuflur; Sodium 3-fluoro-4-phenylhydratropate; Sodium flurbiprofen |
| Storage | Store at -20 °C |
| IUPAC Name | sodium;2-(3-fluoro-4-phenylphenyl)propanoate |
| Canonical SMILES | CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)[O-].[Na+] |
| InChI | InChI=1S/C15H13FO2.Na/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11;/h2-10H,1H3,(H,17,18);/q;+1/p-1 |
| InChI Key | AUAGTGKMTMVIKN-UHFFFAOYSA-M |
| Melting Point | 114-116 °C |
| Solubility | Soluble in DMSO |
1.Hemodynamics of mesenteric traction syndrome measured by FloTrac sensor.
Takahashi H1, Shida D2, Tagawa K3, Suzuki T3. J Clin Anesth. 2016 May;30:46-50. doi: 10.1016/j.jclinane.2015.12.001. Epub 2016 Feb 21.
BACKGROUND: Mesenteric traction syndrome (MTS) develops in the early phase of laparotomy, which is triggered by pulling of the mesentery. We attempted to analyze the circulatory dynamics of MTS by using the FloTrac sensor.
2.Comparison of topically applied flurbiprofen or bromfenac ophthalmic solution on post-operative ocular hypertension in canine patients following cataract surgery.
Lu J1, English R1, Nadelstein B1, Weigt A1, Berdoulay A1, Binder D1, Ngan E1. Vet Ophthalmol. 2016 Mar 18. doi: 10.1111/vop.12372. [Epub ahead of print]
OBJECTIVE: To compare the prevalence and kinetics of ocular hypertension after routine cataract extraction when using a predominately COX-2 inhibitor (bromfenac) versus a predominately COX-1 inhibitor (flurbiprofen) in combination with a topical corticosteroid.
3.The potential use of novel chitosan-coated deformable liposomes in an ocular drug delivery system.
Chen H1, Pan H2, Li P1, Wang H3, Wang X1, Pan W1, Yuan Y4. Colloids Surf B Biointerfaces. 2016 Mar 22;143:455-462. doi: 10.1016/j.colsurfb.2016.03.061. [Epub ahead of print]
In this study, novel chitosan-coated deformable liposomes (DL-CS) were proposed as an ocular drug delivery system to prolong pre-corneal retention, and improve transcorneal penetration and absorption. Flurbiprofen-loaded deformable liposomes (FP-DL) were prepared by a modified ethanol injection method and then coated with chitosan. Both DL and DL-CS exhibited a homogeneous particle size distribution, high encapsulation efficiency and good stability. After coating with 0.1% CS, the zeta potential was shifted from negative to positive. The apparent permeability coefficient of FP-DL-0.1% CS evaluated using isolated rabbit corneas was 1.29-, 1.95- and 4.59- fold greater than that of uncoated FP-DL, conventional liposomes and FP solution (P<0.01), respectively. The in vivo pre-corneal retention time and elimination dynamics were assessed using gamma scintigraphy technology. The area under the remaining activity-time of FP-DL-0.1% CS was prolonged 2.
4.Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M1, Samer C1,2, Déglon J3,4, Thomas A3, Walder B5, Desmeules J1,2, Daali Y1,2. Basic Clin Pharmacol Toxicol. 2016 Mar 24. doi: 10.1111/bcpt.12586. [Epub ahead of print]
Cytochrome P450 (CYP) activity can be assessed using a 'cocktail' phenotyping approach. Recently, we have developed a cocktail (Geneva cocktail) which combines the use of low-dose probes with a low-invasiveness dried blood spots (DBS) sampling technique and a single analytical method for the phenotyping of six major CYP isoforms. We have previously demonstrated that modulation of CYP activity after pre-treatment with CYP inhibitors/inducer could be reliably predicted using Geneva cocktail. In order to further validate this cocktail, in this study we have verified whether probe drugs contained in the latter cause mutual drug-drug interactions. In a randomized, 4-way, Latin-square cross-over study, 30 healthy volunteers received low-dose caffeine, flurbiprofen, omeprazole, dextromethorphan and midazolam (a previously validated combination with no mutual drug-drug interactions); fexofenadine alone; bupropion alone or all 7 drugs simultaneously (Geneva cocktail).
| BBF-03755 | Actinomycin D | Inquiry |
| BBF-03881 | Sancycline | Inquiry |
| BBF-05781 | Emodepside | Inquiry |
| BBF-03756 | Amygdalin | Inquiry |
| BBF-04301 | Tulathromycin A | Inquiry |
| BBF-05808 | Triptolide | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
